Benlysta at lasta: GSK finally snares HGS at $14 a share
This article was originally published in Scrip
Executive Summary
After months of wrangling and hostility, Human Genome Sciences has at last accepted GlaxoSmithKline's takeover bid after the UK-based giant sweetened its offer, adding $1.25 per share to its previous offer of $13 a share. At $14.25 per share, which is what the companies have finally closed on, HGS is valued at about $3.6 billion.